The human dengue challenge experience at the walter reed army institute of research

Journal of Infectious Diseases

Volumn 209, Issue SUPPL. 2, 2014, Pages

  Lyons, Arthur G ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

challenge; dengue; human; virus; walter reed

Indexed keywords

DENGUE VACCINE;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL (TOPIC); DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 3; DISEASE MODEL; FEVER; FLAVIVIRUS; HUMAN; IMMUNITY; IMMUNOGENICITY; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROTYPE; VIREMIA; VIRUS STRAIN; VIRUS TRANSMISSION;

CHALLENGE; DENGUE; HUMAN; VIRUS; WALTER REED;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HEALTHY VOLUNTEERS; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84901793631     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu174     Document Type: Article

References (34)

1. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live attenuated CYD tetravalent dengue vaccine in Thai schoolchildren; a randomized, controlled phase 2b trial. Lancet 2012; 380:1559-67.
2. Graham H. Dengue: a study of its mode of propagation and pathology. Med Rec New York 1902; 61:204-7.
3. Ashburn PM, Craig CF. Experimental investigations regarding the etiology of dengue fever. J Infect Dis 1907; 4:440-75.
4. Cleland JB, Bradley B, MacDonald W. Further experiments in the etiology of dengue fever. J Hyg 1919; 18:217-54.
5. Siler JF, Hall MW, Hitchens AP. Dengue: Its history, epidemiology, mechanism of transmission, etiology, clinical manifestations, immunity, and prevention. Philippine J Sci 1926; 29:1-304.
6. Simmons JS, St. John JH, Reynolds FHK. Experimental studies of dengue. Philippine J Sci 1931; 44:1-252.
7. Sawada T, Sato H, Sai S. On the experimental dengue infection in man. Nippon Igaku 1943; 3325:529-31.
8. Misao T. Clinical aspects of dengue fever. Chiryo (Therapy) 1944; 26:199-218.
9. Taniguchi T, Fujino T, Inoki S, Okuno Y. Studies on the experimental inoculation of dengue fever. Med J Osaka Univ 1951; 2:1-36.
10. Hotta S. Experimental studies in dengue: I. Isolation, identification and modification of the virus. J Infect Dis 1952; 90:1-9.
11. Sabin AB, Schlesinger RW. Production of immunity to dengue with virus modified by propagation in mice. Science 1945; 101:640-2.
12. Schlesinger RW, Gordon I, Frankel JW, et al. Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses. J Immunol 1956; 77:352-64.
13. Okuno Y, Fukanaga T, Tadano M, et al. Serological Studies on volunteers inoculated experimentally with a dengue virus strain in 1943. Biken J 1983; 26:161-3. (Pubitemid 14132344)
14. Mammen MP, Lyons A, Innis BL, et al. Evaluation of dengue virus strains for human challenge studies. Vaccine 2014; 32:1488-94.
15. Sun W, Eckels KH, Putnak JR, et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis 2013; 207:700-8.
16. Kotloff KL. Human challenge studies with infectious agents. J Investig Med 2003; 51 (Suppl 1):S6-11.
17. Sun W, Edelman R, KAnesa-Thasan N, et al. Vaccination of human volunteers with monovalent and trivalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003; 69 (Suppl 6):24-31.
18. Edelman RE, Wasserman SS, Bodison SA, et al. Phase 1 trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69 (Suppl 6):48-60.
19. Sun W, Cunningham D, Wasserman SS, et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naiive adults. Hum Vaccine 2009; 5:33-40.
20. Statler J, Mammen M, Lyons A, Sun W. Sonographic Findings of Healthy Volunteers Infected with Dengue Virus. J Clin Ultrasound 2008; 36:413-7.
21. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 1970; 42:311-28.
22. Watts DM, Porter KR, Putvatana P, et al. Failure of secondary infection with American genotype dengue 2 to cause dengue hemorrhagic fever. Lancet 1999; 354:1431-4. (Pubitemid 29494755)
23. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue virus serotype, virus titers, and antibody response patterns correlate with dengue disease severity. J Infect Dis 2000; 181:2-9. (Pubitemid 30049026)
24. Gubler DJ. Dengue and dengue hemorrhagic fever: its history and resurgence as a global public health problem. In: Gubler DJ, Kuno G, eds. Dengue and dengue hemorrhagic fever. New York: CAB International, 1997:1-22.
25. Kalayanarooj S, Gibbons RV, Vaughn D, et al. Blood group AB is associated with increased risk for severe dengue disease in secondary infections. J Infect Dis 2007; 195:1014-7. (Pubitemid 46452107)
26. Anez G, Men R, Eckels KH, Lai CJ. Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in rhesus macaques. J Virol 2009; 83:10384-94.
27. Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 2000; 6:816-20. (Pubitemid 30469433)
28. Pelupessy JM, Allo ER, Jota S. Pericardial effusion in dengue hemorrhagic fever. Paediatr Indonesia 1989; 29:72-5.
29. Kabra SK, Juneja R, Madhulika, et al. Myocardial dysfunction in children with dengue heaemorrhagic fever. Natl Med J India 1998; 11:59-61. (Pubitemid 128549448)
30. Setiawan MW, Samsi TK, Wulur H, et al. Dengue haemorrhagic fever: ultrasound as an aid to predict the severity of the disease. Pediatr Radiol 1998; 28:1-4. (Pubitemid 28055097)
31. Srikiatkhachorn A, Gibbons RV, Green S, et al. Dengue Hemorrhagic Fever: The Sensitivity and Specificity of the World Health Organization Definition for Identification of Severe Cases of Dengue in Thailand, 1994-2005. Clin Infect Dis 2010; 50:1135-43.
32. Asher LVS, Mammen MP, Lyons AG, et al. Platelet Phagocytosis and Neutrophil Apoptosis Might Account for Thrombocytopenia and Neutropenia in Dengue Patients. Am J Trop Med Hyg 2001; 65 (3 Suppl):388.
33. Asher LVS, Norton AS, Krivda S, et al. Degranulation of Mast Cells in Dengue Patients. Microscopy and Microanalysis 2002; 8 (Suppl 2): 920-21CD.
34. Gunther VJ, Putnak R, Eckels KH, et al. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 2011; 29:3895-904.